Investors

NEW YORK, NY, and CAMBRIDGE, MA NOVEMBER 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million.

NEW YORK, NY, October 17, 2025 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share.

NEW YORK, NY, October 9, 2025 – Royalty Pharma plc today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open.

NEW YORK, NY, September 29, 2025 – Royalty Pharma plc today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.